Business Wire - October 25, 1999
Dr. Johannes Koch, M.D. presented findings from a clinical study he conducted at the University of California San Francisco (UCSF) General Hospital which demonstrated the safety and efficacy of SB-Normal Stool Formula. Dr. Koch presented a summary of research showing that effective anti-diarrhea therapy significantly improves quality of life, time resting, ability to leave home, and sexual activity.
In the first study, SB-Normal Stool Formula was administered for two weeks to 20 people with HIV suffering from diarrhea. The subjects reported a 60% reduction in the number of watery stools per day (from 3.1 to 1.9, p=0.0026) as well as a statistically significant reduction in stool weight (from 598.3 grams to 385.8 grams, p=0.0026).
"The study demonstrated that SB-Normal Stool Formula was well-tolerated and relieved chronic diarrhea for many patients by both stool weight measurement and by a self-reported measurement of improvement," noted Dr. Koch. "SB-Normal Stool Formula represents an exciting new treatment to patients for whom other products often provide little or no relief."
Dr. Koch also presented a summary of data from the safety and efficacy study on SB-Normal Stool Formula combined with the results of a large Phase III trial on the experimental pharmaceutical product SP-303(TM). (SB-Normal Stool Formula contains SP-303 as the principal ingredient.) Dr. Koch evaluated the impact within two to four weeks of treatment on the quality of life of people living with HIV/AIDS who experience chronic diarrhea. These studies showed a statistically significant improvement in the overall quality of life score as well as in specific quality of life parameters of time spent resting, ability to leave home, and sexual activity.
"In addition to other burdens of living with HIV/AIDS infection, many people experience diminished quality of life as a direct result of their chronic diarrhea," said Dr. Koch. "The improvement in quality of life within just a few weeks of responding to treatment is dramatic and speaks to the importance of recognizing the need to treat diarrhea in people with HIV/AIDS."
SB-Normal Stool Formula is a revolutionary new dietary supplement developed by ShamanBotanicals.com(TM). The patented principal ingredient in SB-Normal Stool Formula is SP-303, which has been demonstrated to be safe and effective in clinical tests involving more than 1,200 people. SB-Normal Stool Formula works by normalizing excess water flow in the bowel and promoting normal stool formation without causing constipation.
"SB-Normal Stool Formula is a natural, safe, and effective product that can help normalize loose and watery stools which often present a health and quality of life problem for people living with HIV and AIDS," said Lisa A. Conte, CEO of ShamanBotanicals.com.
Controlling chronic diarrhea is also critical to the ability to adhere to rigorous anti-HIV drug therapy regimens for two reasons: (1) Diarrhea increases the transit time during which medicines pass through the intestinal tract, significantly reducing absorption; and (2) patients who experience chronic diarrhea, a common side effect of protease inhibitors, are less likely to comply with their drug therapy regimen. More than 90% of the patients in these studies were on protease inhibitors.
"Taking SB-Normal Stool Formula helps people to reclaim the control, comfort, and intimacy of their lives," added Conte. SB-Normal Stool Formula is sold direct to customers exclusively through the company's website, www.ShamanBotanicals.com and its toll-free customer service line, 800/987-9920.
Shaman Pharmaceuticals, Inc., through its ShamanBotanicals.com division (OTC BB:SHMNO, Series R Preferred Stock), is focused on the discovery, development and commercialization of proprietary botanical dietary supplements from tropical plants for unmet healthcare needs through community building initiatives on the Internet and other focused channels.
This press release contains, among other things, certain statements of a forward-looking nature relating to Shaman's ability to advance its development and research programs. Such statements involve a number of risks and uncertainties including the Risk Factors listed in the company's SEC filings including, but not limited to, those contained in Shaman Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended Dec. 31, 1998. These filings are available upon request at 650/952-7070. Also, visit Shaman at http://www.ShamanBotanicals.com.
--30--mr/sf*
CONTACT: ShamanBotanicals.com, South San Francisco Corporate Communications, 650/952-7070 x485
991025
BW991004
Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .